Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian Cancer

Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian CancerПодробнее

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian CancerПодробнее

Dr. Mirza on Safety Profile of Niraparib/Bevacizumab in Recurrent Ovarian CancerПодробнее

Dr. Mirza on Niraparib Efficacy Across Ovarian Cancer SubgroupsПодробнее

Combination therapy to treat ovarian cancer: promising results from the ANANOVA trialПодробнее

Dr. Mirza Discusses Niraparib Dose Modifications for Ovarian Cancer Patients With Low Body WeightПодробнее

Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancerПодробнее

Final ANANOVA2 Survival Data Support Niraparib Plus Bevacizumab in Recurrent Ovarian CancerПодробнее

Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian CancerПодробнее

Dr. Mirza on the Rationale for the AVANOVA Trial in Recurrent Ovarian CancerПодробнее

Combination Therapy With Niraparib and Bevacizumab for Ovarian CancerПодробнее

The AVANOVA study: niraparib and bevacizumab for ovarian cancerПодробнее

Dr. Mirza on the Phase III NOVA Trial in Ovarian CancerПодробнее

Dr. Mirza on the Evolving Treatment Landscape in Recurrent Ovarian CancerПодробнее

Dr. Mirza on Impact of Niraparib in Ovarian CancerПодробнее

Treating Ovarian Cancer With Niraparib: The NOVA TrialПодробнее

Dr. Arend on Niraparib With Bevacizumab in Ovarian CancerПодробнее

Data Demonstrate Efficacy of 3 PARP Inhibitors in Ovarian CancerПодробнее

Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?Подробнее